Locations
San Francisco, CA, USA · Richmond, CA, USA
industry
Biotechnology · Consumer Products · DeepTech · Hardware
Size
51-200 employees
Stage
Series C+
founded in
2015
BioAge Labs is focused on harnessing the biology of human aging to develop innovative therapies for metabolic diseases, particularly obesity. Their lead product, azelaprag, is positioned as a first-in-class oral weight loss therapy that works in conjunction with incretin drugs to achieve significant weight loss. The company utilizes a proprietary human-first discovery platform that analyzes extensive multi-omics data to identify molecular mediators of aging and disease. With a strong leadership team boasting over 95 regulatory approvals, BioAge Labs is well-positioned in the biopharma sector, targeting key pathways that drive metabolic aging and addressing a critical health challenge.
Something looks off?